12:00 AM
 | 
Mar 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

DP-b99: Development discontinued

D-Pharm discontinued development of DP-b99 to treat stroke after an interim analysis of the double-blind, placebo-controlled, international Phase III MACSI trial showed that the compound met undisclosed criteria for futility. No safety concerns were identified. The trial was evaluating 1 mg/kg/day IV DP-b99 for 4 consecutive days initiated up...

Read the full 224 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >